Efficacy and Safety of Anti–Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial

Introduction: The study (ClinicalTrials.gov, NCT04346914) is an open label, single-arm, phase 1b clinical trial investigating the safety, tolerability, and efficacy of the recombinant human anti–programmed death-ligand 1 monoclonal antibody socazolimab in combination with carboplatin and etoposide i...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Shun Lu, PhD, MD, Zhiwei Chen, MD, Jiuwei Cui, MD, Renhua Guo, MD, Ziming Li, MD, Benjamin Xiaoyi Li, PhD, Xiangrong Dai, PhD
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2023-04-01
Sarja:	JTO Clinical and Research Reports
Aiheet:	Socazolimab Extensive-stage small cell lung cancer (ES-SCLC) Carboplatin Etoposide PD-L1
Linkit:	http://www.sciencedirect.com/science/article/pii/S2666364323000176
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!